|
Placebo and atypical antipsychotic response rates of selected comparator trials |
||||||
| Comparator |
Study design |
Dose (mg/day) |
Definition of response |
Placebo response rate (%) |
Atypical response rate (%) |
Reference(s) |
|
|
||||||
| Paliperidone ER |
6 week study, patients with schizophrenia and acute exacerbation, olanzapine comparator |
3, 6, 9, and 12 |
≥ 30% decrease in PANSS from baseline to study endpoint |
27.4 |
50.8 |
[21] [22] [23] |
| Risperidone |
4 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation, aripiprazole comparator |
6 |
≥ 30% decrease in PANSS from baseline to study endpoint or CGI-I ≤ 2 |
23.3 |
40.0 |
[35] |
| Olanzapine |
6 week study, patients with schizophrenia and acute exacerbation, paliperidone ER comparator |
10 |
≥ 30% decrease in PANSS from baseline to study endpoint |
27.4 |
50.1 |
[21] [22] [23] |
| Quetiapine |
6 week study, inpatients with chronic or subchronic schizophrenia and acute exacerbation |
750 |
≥ 30% decrease in BPRS at any time during treatment |
35.0 |
49.0 |
[41] |
| Ziprasidone |
6 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation |
80 and 160 |
≥ 30% decrease in PANSS from baseline to study endpoint |
17.6 |
29.9 |
[44] |
| Aripiprazole |
4 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation, risperidone comparator |
20 and 30 |
≥ 30% decrease in PANSS from baseline to study endpoint or CGI-I ≤ 2 |
23.3 |
38.1 |
[35] |
|
BPRS, Brief Psychiatric Rating Scale; CGI-I, Clinical Global Impression – Improvement; PANSS, Positive and Negative Syndrome Scale. | ||||||
Geitona et al. Annals of General Psychiatry 2008 7:16 doi:10.1186/1744-859X-7-16 |
||||||